KR100919141B1 - 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 - Google Patents
치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 Download PDFInfo
- Publication number
- KR100919141B1 KR100919141B1 KR1020047000898A KR20047000898A KR100919141B1 KR 100919141 B1 KR100919141 B1 KR 100919141B1 KR 1020047000898 A KR1020047000898 A KR 1020047000898A KR 20047000898 A KR20047000898 A KR 20047000898A KR 100919141 B1 KR100919141 B1 KR 100919141B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- yloxy
- formula
- methyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Lubricants (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Paper (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30662101P | 2001-07-19 | 2001-07-19 | |
| US60/306,621 | 2001-07-19 | ||
| PCT/US2002/022897 WO2003008411A1 (en) | 2001-07-19 | 2002-07-18 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040029374A KR20040029374A (ko) | 2004-04-06 |
| KR100919141B1 true KR100919141B1 (ko) | 2009-09-25 |
Family
ID=23186103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047000898A Expired - Fee Related KR100919141B1 (ko) | 2001-07-19 | 2002-07-18 | 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6930111B2 (https=) |
| EP (1) | EP1406898B1 (https=) |
| JP (1) | JP2004537554A (https=) |
| KR (1) | KR100919141B1 (https=) |
| CN (1) | CN1533388A (https=) |
| AT (1) | ATE292633T1 (https=) |
| AU (1) | AU2008202958A1 (https=) |
| CA (1) | CA2454059A1 (https=) |
| DE (1) | DE60203623T2 (https=) |
| DK (1) | DK1406898T3 (https=) |
| ES (1) | ES2236557T3 (https=) |
| HU (1) | HUP0402088A3 (https=) |
| IL (1) | IL159897A0 (https=) |
| MX (1) | MXPA04000565A (https=) |
| NO (1) | NO327635B1 (https=) |
| NZ (1) | NZ530705A (https=) |
| PL (1) | PL368529A1 (https=) |
| PT (1) | PT1406898E (https=) |
| RU (1) | RU2300533C2 (https=) |
| WO (1) | WO2003008411A1 (https=) |
| ZA (1) | ZA200400404B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001909B2 (en) * | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| MXPA04011530A (es) | 2002-05-21 | 2005-08-15 | Cv Therapeutics Inc | Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes. |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| MXPA05001592A (es) * | 2002-08-09 | 2005-05-05 | Astrazeneca Ab | Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico. |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| EP1806346B1 (en) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| AU2003300827B2 (en) * | 2002-12-05 | 2009-08-13 | Gilead Palo Alto, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| NZ541069A (en) | 2003-01-03 | 2008-09-26 | Cv Therapeutics Inc | Piperazine derivatives as fatty acid oxidation inhibitors |
| NZ541306A (en) * | 2003-01-17 | 2008-07-31 | Cv Therapeutics Inc | Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases |
| NZ544449A (en) * | 2003-06-23 | 2008-10-31 | Cv Therapeutics Inc | Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| EP1723129A1 (en) * | 2003-12-18 | 2006-11-22 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| US7959659B2 (en) * | 2004-01-02 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| WO2006029179A2 (en) * | 2004-09-08 | 2006-03-16 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| WO2008023248A2 (en) | 2006-08-24 | 2008-02-28 | Wockhardt Research Centre | Novel macrolides and ketolides having antimicrobial activity |
| US8088920B2 (en) * | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| HRP20170357T1 (hr) | 2008-10-10 | 2017-05-05 | Vm Discovery, Inc. | Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti |
| JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｎｓ障害の治療のためのラノラジン |
| JPWO2011115150A1 (ja) * | 2010-03-18 | 2013-07-04 | 興和株式会社 | ベンゾチアジン化合物の製造方法 |
| CN111285819A (zh) * | 2018-12-07 | 2020-06-16 | 江苏恩华药业股份有限公司 | 一种苯并噁唑类化合物及其应用 |
| WO2023023995A1 (zh) * | 2021-08-25 | 2023-03-02 | 苏州大学 | 一种防治心肌缺血后心功能衰竭的药物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1133989A (en) | 1964-12-08 | 1968-11-20 | Chugai Pharmaceutical Co Ltd | Theophylline derivatives, their salts and process for preparing the same |
| DE2834114A1 (de) * | 1978-08-01 | 1980-02-14 | Schering Ag | Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| JPS6137765A (ja) * | 1984-07-19 | 1986-02-22 | サンド・アクチエンゲゼルシヤフト | ３‐アミノプロポキシアリール誘導体 |
| US4723014A (en) * | 1986-11-19 | 1988-02-02 | Warner-Lambert Company | Process for the preparation of 2-substituted-1,4-dihydropyridines |
| DE3723648A1 (de) * | 1987-07-17 | 1989-01-26 | Sandoz Ag | Indol-derivate, ihre herstellung und sie enthaltende arzneimittel |
| JPH0699399B2 (ja) * | 1988-10-06 | 1994-12-07 | 三井東圧化学株式会社 | 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤 |
| JPH02268162A (ja) * | 1989-04-10 | 1990-11-01 | Fujisawa Pharmaceut Co Ltd | ジフェニルピリジン誘導体 |
| MX9308025A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. |
| EP0938480A1 (en) * | 1996-11-14 | 1999-09-01 | American Home Products Corporation | Substituted tetrahydro-1,3,5-triazin-2 1h]-thiones as anti-atherosclerotic agents |
| HK1044777B (en) * | 1999-09-13 | 2006-04-13 | Wyeth | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| SE9904765D0 (sv) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically-useful compounds |
| AU2001238590A1 (en) | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| IL151178A0 (en) | 2000-02-22 | 2003-04-10 | Cv Therapeutics Inc | Substituted piperazine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| AU2001239827A1 (en) * | 2000-02-22 | 2001-09-03 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| SE0003795D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Pharmaceutically useful compounds |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
-
2002
- 2002-07-18 WO PCT/US2002/022897 patent/WO2003008411A1/en not_active Ceased
- 2002-07-18 EP EP02756522A patent/EP1406898B1/en not_active Expired - Lifetime
- 2002-07-18 IL IL15989702A patent/IL159897A0/xx unknown
- 2002-07-18 AT AT02756522T patent/ATE292633T1/de not_active IP Right Cessation
- 2002-07-18 NZ NZ530705A patent/NZ530705A/en not_active IP Right Cessation
- 2002-07-18 JP JP2003513970A patent/JP2004537554A/ja not_active Ceased
- 2002-07-18 DK DK02756522T patent/DK1406898T3/da active
- 2002-07-18 KR KR1020047000898A patent/KR100919141B1/ko not_active Expired - Fee Related
- 2002-07-18 PT PT02756522T patent/PT1406898E/pt unknown
- 2002-07-18 US US10/198,237 patent/US6930111B2/en not_active Expired - Fee Related
- 2002-07-18 CA CA002454059A patent/CA2454059A1/en not_active Abandoned
- 2002-07-18 DE DE60203623T patent/DE60203623T2/de not_active Expired - Fee Related
- 2002-07-18 HU HU0402088A patent/HUP0402088A3/hu unknown
- 2002-07-18 RU RU2004104951/04A patent/RU2300533C2/ru not_active IP Right Cessation
- 2002-07-18 MX MXPA04000565A patent/MXPA04000565A/es active IP Right Grant
- 2002-07-18 ES ES02756522T patent/ES2236557T3/es not_active Expired - Lifetime
- 2002-07-18 CN CNA02814371XA patent/CN1533388A/zh active Pending
- 2002-07-18 PL PL02368529A patent/PL368529A1/xx not_active Application Discontinuation
-
2004
- 2004-01-19 ZA ZA200400404A patent/ZA200400404B/en unknown
- 2004-01-19 NO NO20040234A patent/NO327635B1/no not_active IP Right Cessation
-
2008
- 2008-07-03 AU AU2008202958A patent/AU2008202958A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| 논문 J.Med.Chem.(1997) |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004537554A (ja) | 2004-12-16 |
| DE60203623T2 (de) | 2006-01-19 |
| WO2003008411A1 (en) | 2003-01-30 |
| US6930111B2 (en) | 2005-08-16 |
| ATE292633T1 (de) | 2005-04-15 |
| RU2300533C2 (ru) | 2007-06-10 |
| HUP0402088A3 (en) | 2010-03-29 |
| CA2454059A1 (en) | 2003-01-30 |
| HK1064374A1 (en) | 2005-01-28 |
| AU2008202958A1 (en) | 2008-07-31 |
| AU2002322527A2 (en) | 2003-03-03 |
| NZ530705A (en) | 2005-08-26 |
| US20030181352A1 (en) | 2003-09-25 |
| ES2236557T3 (es) | 2005-07-16 |
| KR20040029374A (ko) | 2004-04-06 |
| EP1406898A1 (en) | 2004-04-14 |
| HUP0402088A2 (hu) | 2005-02-28 |
| IL159897A0 (en) | 2004-06-20 |
| PL368529A1 (en) | 2005-04-04 |
| ZA200400404B (en) | 2004-10-14 |
| DE60203623D1 (de) | 2005-05-12 |
| MXPA04000565A (es) | 2005-06-17 |
| EP1406898B1 (en) | 2005-04-06 |
| PT1406898E (pt) | 2005-08-31 |
| AU2002322527B2 (en) | 2008-04-17 |
| NO20040234L (no) | 2004-03-18 |
| NO327635B1 (no) | 2009-09-07 |
| DK1406898T3 (da) | 2005-05-30 |
| RU2004104951A (ru) | 2005-06-27 |
| CN1533388A (zh) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100919141B1 (ko) | 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 | |
| US7001909B2 (en) | Substituted heterocyclic compounds | |
| US7026321B2 (en) | Substituted heterocyclic compounds | |
| AU2003300827B2 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| US7056924B2 (en) | Substituted heterocyclic compounds | |
| AU2002322527C1 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| AU2002322527A1 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| HK1064374B (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| HK1083492B (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| KR20070051305A (ko) | 치환된 피페라진 화합물 및 지방산 산화 저해제로서의 이의용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| J201 | Request for trial against refusal decision | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20120922 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20120922 |